CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Clovis Oncology Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Clovis Oncology Inc Bankruptcy Case Study!
Suite 100, 2525 28Th Street
Phone: (303) 625-5000p:303 625-5000 BOULDER, CO  80301  United States Fax: (302) 655-5049f:302 655-5049
This company's Plan of Liquidation went into effect on 7/10/2023
This company ceased filing statements with the SEC on 7/11/2023.
This entity represents the bankrupt estate of the former businesses (assets) of Clovis Oncology Inc that were not sold to pharma& Schweiz GmbH on 5/1/2023.
This company is no longer actively traded on any major stock exchange.
Business Summary
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and an indication specific to metastatic castration-resistant prostate cancer (mCRPC). Its FAP-2286 is a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP). It also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR a/ß) and fibroblast growth factor receptors 1 through 3 (FGFR1-3).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202212/31/2021YesYesYes-Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Ginger L.Graham 67 6/5/2019 6/13/2013
President, Chief Executive Officer, Co-Founder, Director Patrick J.Mahaffy 59 4/20/2009 4/20/2009
Co-Founder, Executive Vice President, Chief Regulatory Officer Gillian C.Ivers - Read 68 4/20/2009 4/20/2009
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Clovis Oncology Denmark ApS Amerika Plads 37 Kobenhavno Denmark
Clovis Oncology IT Srl Regus Broletto Milan Italy
Clovis Oncology Germany GmbH Theatinerstrasse 11, 8th Floor Munich Germany
3 additional Subsidiary records available in full report.

Business Names
Business Name
C6O
Clovis Oncology Denmark ApS
Clovis Oncology France SAS
13 additional Business Names available in full report.

General Information
Outstanding Shares: 144,955,263 (As of 11/4/2022)
Shareholders: 26
Stock Exchange: MNC
Federal Tax Id: 900475355
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, November 18, 2024